Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer

被引:139
作者
Daige, Christopher L. [1 ]
Wiggins, Jason F. [1 ]
Priddy, Leslie [1 ]
Nelligan-Davis, Terri [1 ]
Zhao, Jane [1 ]
Brown, David [1 ]
机构
[1] Mirna Therapeut Inc, Austin, TX 78744 USA
关键词
HEDGEHOG SIGNALING PATHWAY; GROWTH-FACTOR-BETA; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; MIR-34A; EXPRESSION; APOPTOSIS; INVASION; METASTASIS; PREDICTION;
D O I
10.1158/1535-7163.MCT-14-0209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
miR34a is a tumor-suppressor miRNA that functions within the p53 pathway to regulate cell-cycle progression and apoptosis. With apparent roles in metastasis and cancer stem cell development, miR34a provides an interesting opportunity for therapeutic development. A mimic of miR34a was complexed with an amphoteric liposomal formulation and tested in two different orthotopic models of liver cancer. Systemic dosing of the formulated miR34a mimic increased the levels of miR34a in tumors by approximately 1,000-fold and caused statistically significant decreases in the mRNA levels of several miR34a targets. The administration of the formulated miR34a mimic caused significant tumor growth inhibition in both models of liver cancer, and tumor regression was observed in more than one third of the animals. The antitumor activity was observed in the absence of any immunostimulatory effects or dose-limiting toxicities. Accumulation of the formulated miR34a mimic was also noted in the spleen, lung, and kidney, suggesting the potential for therapeutic use in other cancers. (C) 2014 AACR.
引用
收藏
页码:2352 / 2360
页数:9
相关论文
共 44 条
[1]   Amphoteric Liposomes Enable Systemic Antigen-Presenting Cell-Directed Delivery of CD40 Antisense and Are Therapeutically Effective in Experimental Arthritis [J].
Andreakos, Evangelos ;
Rauchhaus, Una ;
Stavropoulos, Athanassios ;
Endert, Gerold ;
Wendisch, Volkmar ;
Benahmed, Amina S. ;
Giaglis, Stavros ;
Karras, James ;
Lee, Sam ;
Gaus, Hans ;
Bennett, C. Frank ;
Williams, Richard O. ;
Sideras, Paschalis ;
Panzner, Steffen .
ARTHRITIS AND RHEUMATISM, 2009, 60 (04) :994-1005
[2]  
[Anonymous], INT J HEPATOL
[3]   The Promise of MicroRNA Replacement Therapy [J].
Bader, Andreas G. ;
Brown, David ;
Winkler, Matthew .
CANCER RESEARCH, 2010, 70 (18) :7027-7030
[4]   Mining the Wnt pathway for cancer therapeutics [J].
Barker, Nick ;
Clevers, Hans .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (12) :997-1014
[5]   Wnt/β-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology [J].
Cavard, Catherine ;
Colnot, Sabine ;
Audard, Virginie ;
Benhamouche, Samira ;
Finzi, Laetitia ;
Torre, Cyril ;
Grimber, Gisele ;
Godard, Cecile ;
Terris, Benoit ;
Perrett, Christine .
FUTURE ONCOLOGY, 2008, 4 (05) :647-660
[6]   Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells [J].
Cheng, Wei-Ting ;
Xu, Kai ;
Tian, De-Ying ;
Zhang, Zheng-Gang ;
Liu, Li-Jiang ;
Chen, Ying .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 34 (03) :829-836
[7]   Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo [J].
Craig, V. J. ;
Tzankov, A. ;
Flori, M. ;
Schmid, C. A. ;
Bader, A. G. ;
Mueller, A. .
LEUKEMIA, 2012, 26 (11) :2421-2424
[8]   Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab [J].
Finn, Richard S. ;
Zhu, Andrew X. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) :503-509
[9]   Commentary: Novel therapies for cancer: Why dirty might be better [J].
Fojo, Tito .
ONCOLOGIST, 2008, 13 (03) :277-283
[10]   Coordinated Regulation of Cell Cycle Transcripts by p53-inducible microRNAs, miR-192 and miR-215 [J].
Georges, Sara A. ;
Biery, Matthew C. ;
Kim, Soo-yeon ;
Schelter, Janell M. ;
Guo, Jane ;
Chang, Aaron N. ;
Jackson, Aimee L. ;
Carleton, Michael O. ;
Linsley, Peter S. ;
Cleary, Michele A. ;
Chau, B. Nelson .
CANCER RESEARCH, 2008, 68 (24) :10105-10112